CASI PHARMACEUTICALS INC (CASI) Stock Fundamental Analysis

NASDAQ:CASI • KYG1933S1012

0.7484 USD
-0.02 (-2.81%)
Last: Feb 12, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CASI. CASI was compared to 523 industry peers in the Biotechnology industry. Both the profitability and financial health of CASI have multiple concerns. CASI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CASI had negative earnings in the past year.
  • In the past 5 years CASI always reported negative net income.
  • In the past 5 years CASI always reported negative operating cash flow.
CASI Yearly Net Income VS EBIT VS OCF VS FCFCASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of CASI (-150.05%) is worse than 84.32% of its industry peers.
Industry RankSector Rank
ROA -150.05%
ROE N/A
ROIC N/A
ROA(3y)-50.53%
ROA(5y)-43.18%
ROE(3y)-774.83%
ROE(5y)-485.42%
ROIC(3y)N/A
ROIC(5y)N/A
CASI Yearly ROA, ROE, ROICCASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

  • CASI's Gross Margin of 56.23% is fine compared to the rest of the industry. CASI outperforms 77.44% of its industry peers.
  • CASI's Gross Margin has improved in the last couple of years.
  • CASI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.45%
GM growth 5Y63.76%
CASI Yearly Profit, Operating, Gross MarginsCASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • CASI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CASI has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CASI has more shares outstanding
  • CASI has a worse debt/assets ratio than last year.
CASI Yearly Shares OutstandingCASI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CASI Yearly Total Debt VS Total AssetsCASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • CASI has an Altman-Z score of -36.20. This is a bad value and indicates that CASI is not financially healthy and even has some risk of bankruptcy.
  • CASI's Altman-Z score of -36.20 is on the low side compared to the rest of the industry. CASI is outperformed by 89.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.2
ROIC/WACCN/A
WACC8.72%
CASI Yearly LT Debt VS Equity VS FCFCASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • CASI has a Current Ratio of 0.47. This is a bad value and indicates that CASI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CASI has a worse Current ratio (0.47) than 90.06% of its industry peers.
  • CASI has a Quick Ratio of 0.47. This is a bad value and indicates that CASI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of CASI (0.38) is worse than 90.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.38
CASI Yearly Current Assets VS Current LiabilitesCASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 40.59% over the past year.
  • The Revenue for CASI has decreased by -21.41% in the past year. This is quite bad
  • The Revenue has been growing by 30.80% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)40.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.82%
Revenue 1Y (TTM)-21.41%
Revenue growth 3Y30.8%
Revenue growth 5YN/A
Sales Q2Q%-60.54%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.53% on average over the next years. This is a very strong growth
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-29.27%
EPS Next 2Y-14.14%
EPS Next 3Y8.8%
EPS Next 5Y21.53%
Revenue Next Year-45.64%
Revenue Next 2Y-39.14%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CASI Yearly Revenue VS EstimatesCASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 20M 40M 60M
CASI Yearly EPS VS EstimatesCASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CASI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CASI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CASI Price Earnings VS Forward Price EarningsCASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CASI Per share dataCASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.14%
EPS Next 3Y8.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CASI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CASI PHARMACEUTICALS INC

NASDAQ:CASI (2/12/2026, 8:00:02 PM)

0.7484

-0.02 (-2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners34.42%
Inst Owner ChangeN/A
Ins Owners29.22%
Ins Owner Change0%
Market Cap15.38M
Revenue(TTM)33.88M
Net Income(TTM)-46.52M
Analysts82.86
Price Target4.08 (445.16%)
Short Float %0.73%
Short Ratio1.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-45.14%
Min EPS beat(2)-79.39%
Max EPS beat(2)-10.9%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-17.37%
Min Revenue beat(2)-35.03%
Max Revenue beat(2)0.29%
Revenue beat(4)3
Avg Revenue beat(4)27.48%
Min Revenue beat(4)-35.03%
Max Revenue beat(4)77.09%
Revenue beat(8)3
Avg Revenue beat(8)-2.41%
Revenue beat(12)5
Avg Revenue beat(12)0.48%
Revenue beat(16)7
Avg Revenue beat(16)0.83%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)29.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.02
EYN/A
EPS(NY)-2.63
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.54
BVpS-1.02
TBVpS-1.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -150.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.23%
FCFM N/A
ROA(3y)-50.53%
ROA(5y)-43.18%
ROE(3y)-774.83%
ROE(5y)-485.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.45%
GM growth 5Y63.76%
F-ScoreN/A
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.38
Altman-Z -36.2
F-ScoreN/A
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)100.64%
Cap/Depr(5y)428.5%
Cap/Sales(3y)6.82%
Cap/Sales(5y)39.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.82%
EPS Next Y-29.27%
EPS Next 2Y-14.14%
EPS Next 3Y8.8%
EPS Next 5Y21.53%
Revenue 1Y (TTM)-21.41%
Revenue growth 3Y30.8%
Revenue growth 5YN/A
Sales Q2Q%-60.54%
Revenue Next Year-45.64%
Revenue Next 2Y-39.14%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.36%
OCF growth 3YN/A
OCF growth 5YN/A

CASI PHARMACEUTICALS INC / CASI FAQ

Can you provide the ChartMill fundamental rating for CASI PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to CASI.


What is the valuation status of CASI PHARMACEUTICALS INC (CASI) stock?

ChartMill assigns a valuation rating of 0 / 10 to CASI PHARMACEUTICALS INC (CASI). This can be considered as Overvalued.


Can you provide the profitability details for CASI PHARMACEUTICALS INC?

CASI PHARMACEUTICALS INC (CASI) has a profitability rating of 1 / 10.


What is the expected EPS growth for CASI PHARMACEUTICALS INC (CASI) stock?

The Earnings per Share (EPS) of CASI PHARMACEUTICALS INC (CASI) is expected to decline by -29.27% in the next year.